Eur Rev Med Pharmacol Sci 2017; 21 (2): 284-291

Diagnostic value of microRNAs in breast cancer: a meta-analysis

Z.-C. Xin, H.-Q. Yang, X.-W. Wang, Q. Zhang

The Second Clinic Medical College, NanChang University, Nanchang, China. zhangqianjining@163.com


OBJECTIVE: To explore the value of diagnosis accuracy of aberrant microRNAs in breast cancer.

MATERIALS AND METHODS: We searched PubMed, Embase, EBSCO and the Cochrane Library, accessing to the case of articles about microRNA expression in breast carcinoma patients after literature screening and quality assessment, extracting data from included studies and using Stata 14.0 analysis data for meta-analysis.

RESULTS: 14 English studies met the inclusion criteria. After meta-analysis for included studies obtained high sensitivity and specificity and diagnostic odds ratio, the combined OR value is 17.96 (95% CI: 11.42-28.42), sensitivity is 0.85 (95% CI: 0.81-0.88), specificity is 0.77 (95% CI: 0.69-0.82), diagnostic odds ratio is 18 (95% CI: 12-29), operating characteristic area under the curve is 0.88 (95% CI: 0.85-0.91).

CONCLUSIONS: The microRNAs can be used as a clinical auxiliary reference index for diagnosis of breast cancer.

Free PDF Download

To cite this article

Z.-C. Xin, H.-Q. Yang, X.-W. Wang, Q. Zhang
Diagnostic value of microRNAs in breast cancer: a meta-analysis

Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 2
Pages: 284-291